AGP Executive Report
Last update: 2 hours agoUS–Liechtenstein Pharma Tariffs: The US Commerce Department says it will apply a 0% ad valorem tariff to certain specialty drugs and ingredients from India and 19 other jurisdictions, including Liechtenstein, as a 100% tariff on some patented pharma imports approaches on Sept 29. The carve-out covers medicines for rare diseases and other categories like infertility treatments, cell and gene therapies, antibody-drug conjugates, and animal pharmaceuticals—plus qualifying components. EU Rare Disease Treatment: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone) for male cerebral adrenoleukodystrophy (cALD) patients aged 2–12 with Gd-negative brain lesions, described as the first pharmacological option for early intervention in the EU. TB in Switzerland: Switzerland reported 544 tuberculosis infections in 2025 (including Liechtenstein), the highest since 2018, with the rise driven mainly by people of foreign origin. Health Funding Scandal (Malta): Malta’s Passports Fund halted €10m health-centre upgrades after procurement and compliance concerns, following findings tied to irregular refurbishment projects.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
